Variation in IL10 and other genes involved in the immune response and in oxidation and prostate cancer recurrence

Cancer Epidemiology Biomarkers and Prevention

Volumn 21, Issue 10, 2012, Pages 1774-1782

  Dluzniewski, Paul J ^a   Wang, Ming Hsi ^a   Zheng, Siqun Lilly ^d   De Marzo, Angelo M ^b,c   Drake, Charles G ^b,c   Fedor, Helen L ^b   Partin, Alan W ^b   Han, Misop ^b   Fallin, M Daniele ^a   Xu, Jianfeng ^d   Isaacs, William B ^b,c   Platz, Elizabeth A ^a,b,c  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; COPPER ZINC SUPEROXIDE DISMUTASE; DNA; DNA GLYCOSYLTRANSFERASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; EXTRACELLULAR SUPEROXIDE DISMUTASE; GLUTATHIONE PEROXIDASE 1; GLUTATHIONE REDUCTASE; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MANGANESE SUPEROXIDE DISMUTASE; MYELOPEROXIDASE; OXOGUANINE DNA GLYCOSYLASE 1; PARAFFIN; REACTIVE OXYGEN METABOLITE; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ADULT; ALLELE; ARTICLE; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER PATIENT; CANCER RECURRENCE; CANCER RISK; CANCER SURGERY; CASE CONTROL STUDY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DETOXIFICATION; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE SEVERITY; DNA DAMAGE; DNA EXTRACTION; DNA REPAIR; GENE EXPRESSION; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; GERM LINE; HAPLOTYPE; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PREVALENCE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN FUNCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TISSUE SECTION;

AGED; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; GENETIC VARIATION; GLUTATHIONE S-TRANSFERASE PI; HAPLOTYPES; HUMANS; INTERLEUKIN-10; INTERLEUKIN-1BETA; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OXIDATION-REDUCTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC NEOPLASMS;

EID: 84867303446     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-12-0458     Document Type: Article

References (43)

1. De Marzo AM, Platz EA, Sutcliffe S, Xu J, Gronberg H, Drake CG, et al. Inflammation in prostate carcinogenesis. Nat Rev Cancer 2007;7:256-69. (Pubitemid 46486616)
2. De Marzo AM, Marchi VL, Epstein JI, Nelson WG. Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am J Pathol 1999;155:1985-92.
3. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420:860-7. (Pubitemid 36019639)
4. Davidsson S, Fiorentino M, Andren O, Fang F, Mucci LA, Varenhorst E, et al. Inflammation, focal atrophic lesions, and prostatic intraepithelial neoplasia with respect to risk of lethal prostate cancer. Cancer Epidemiol Biomarkers Prev 2011;20:2280-7.
5. Irani J, Goujon JM, Ragni E, Peyrat L, Hubert J, Saint F, et al. High-grade inflammation in prostate cancer as a prognostic factor for biochemical recurrence after radical prostatectomy. Pathologist Multi Center Study Group. Urology 1999;54:467-72. (Pubitemid 29407023)
6. McCarron SL, Edwards S, Evans PR, Gibbs R, Dearnaley DP, Dowe A, et al. Influence of cytokine gene polymorphisms on the development of prostate cancer. Cancer Res 2002;62:3369-72. (Pubitemid 34651380)
7. Faupel-Badger JM, Kidd LC, Albanes D, Virtamo J, Woodson K, Tangrea JA. Association of IL-10 polymorphisms with prostate cancer risk and grade of disease. Cancer Causes Control 2008;19:119-24.
8. Wang MH, Helzlsouer KJ, Smith MW, Hoffman-Bolton JA, Clipp SL, Grinberg V, et al. Association of IL10 and other immune response- and obesity-related genes with prostate cancer in CLUE II. Prostate 2009;69:874-85.
9. Lin HC, Liu CC, Kang WY, Yu CC, Wu TT, Wang JS, et al. Influence of cytokine gene polymorphismson prostate-specific antigen recurrence in prostate cancer after radical prostatectomy. Urol Int 2009;83:463-70.
10. Wang MH, Shugart YY, Cole SR, Platz EA. A simulation study of control sampling methods for nested case-control studies of genetic and molecular biomarkers and prostate cancer progression. Cancer Epidemiol Biomarkers Prev 2009;18:706-11.
11. Beer TM, Lalani AS, Lee S, Mori M, Eilers KM, Curd JG, et al. C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer: results from the ASCENT trial. Cancer 2008;112:2377-83.
12. Zhang H, Xu Y, Li L, Liu R, Ma B. The interleukin-6-174G/C polymorphism and prostate cancer risk: a systematic review and meta-analysis. Urol Int 2012;88:447-53.
13. http://www.broad.mit.edu/mpg/tagger/server.html. Accessed on September-October 2005.
14. http://www.ncbi.nlm.nih.gov. Accessed on September-October 2005.
15. http://hapmap.ncbi.nlm.nih.gov/. Accessed on June 18, 2011.
16. Crawley E, Kay R, Sillibourne J, Patel P, Hutchinson I, Woo P. Polymorphic haplotypes of the interleukin-10 50 flanking region determine variable interleukin-10 transcription and are associated with particular phenotypes of juvenile rheumatoid arthritis. Arthritis Rheum 1999;42:1101-8. (Pubitemid 29268946)
17. Kilpinen S, Huhtala H, Hurme M. The combination of the interleukin-1alpha (IL-1alpha-889) genotype and the interleukin-10 (IL-10 ATA) haplotype is associated with increased interleukin-10 (IL-10) plasma levels in healthy individuals. Eur Cytokine Netw 2002;13:66-71. (Pubitemid 34535573)
18. Stearns ME, Rhim J, Wang M. Interleukin 10 (IL-10) inhibition of primary human prostate cell-induced angiogenesis: IL-10 stimulation of tissue inhibitor of metalloproteinase-1 and inhibition of matrix metalloproteinase (MMP)-2/MMP-9 secretion. Clin Cancer Res 1999;5:189-96. (Pubitemid 29045193)
19. Wang M, Hu Y, Shima I, Stearns ME. IL-10/IL-10 receptor signaling regulates TIMP-1 expression in primary human prostate tumor lines. Cancer Biol Ther 2002;1:556-63.
20. Stearns ME, Kim G, Garcia F, Wang M. Interleukin-10 induced activating transcription factor 3 transcriptional suppression of matrix metalloproteinase-2 gene expression in human prostate CPTX-1532 Cells. Mol Cancer Res 2004;2:403-16. (Pubitemid 39031074)
21. Lange LA, Carlson CS, Hindorff LA, Lange EM, Walston J, Durda JP, et al. Association of polymorphisms in the CRP gene with circulating C-reactive protein levels and cardiovascular events. JAMA 2006;296:2703-11. (Pubitemid 44917547)
22. Miller DT, Zee RY, Suk Danik J, Kozlowski P, Chasman DI, Lazarus R, et al. Association of common CRP gene variants with CRP levels and cardiovascular events. Ann Hum Genet 2005;69(Pt 6):623-38. (Pubitemid 41556317)
23. Suk HJ, Ridker PM, Cook NR, Zee RY. Relation of polymorphism within the C-reactive protein gene and plasma CRP levels. Atherosclerosis 2005;178:139-45. (Pubitemid 39600826)
24. Carlson CS, Aldred SF, Lee PK, Tracy RP, Schwartz SM, Rieder M, et al. Polymorphisms within the C-reactive protein (CRP) promoter region are associated with plasma CRP levels. Am J Hum Genet 2005;77:64-77. (Pubitemid 40848037)
25. Stark JR, Li H, Kraft P, Kurth T, Giovannucci EL, Stampfer MJ, et al. Circulating prediagnostic interleukin-6 and C-reactive protein and prostate cancer incidence and mortality. Int J Cancer 2009;124:2683-9.
26. Pierce BL, Biggs ML, DeCambre M, Reiner AP, Li C, Fitzpatrick A, et al. C-reactive protein, interleukin-6, and prostate cancer risk in men aged 65 years and older. Cancer Causes Control 2009;20:1193-203.
27. Helzlsouer KJ, Erlinger TP, Platz EA. C-reactive protein levels and subsequent cancer outcomes: results from a prospective cohort study. Eur J Cancer 2006;42:704-7.
28. Prins RC, Rademacher BL, Mongoue-Tchokote S, Alumkal JJ, Graff JN, Eilers KM, et al. C-reactive protein as an adverse prognostic marker for men with castration-resistant prostate cancer (CRPC): confirmatory results. Urol Oncol 2012;30:33-7.
29. Hu X, Pal A, Krzeminski J, Amin S, Awasthi YC, Zimniak P, et al. Specificities of human glutathione S-transferase isozymes toward anti-diol epoxides of methylchrysenes. Carcinogenesis 1998;19:1685-9. (Pubitemid 28441874)
30. De Marzo AM, Meeker AK, Zha S, Luo J, Nakayama M, Platz EA, et al. Human prostate cancer precursors and pathobiology. Urology 2003;62(5 Suppl 1):55-62. (Pubitemid 37371890)
31. Mo Z, Gao Y, Cao Y, Gao F, Jian L. An updating meta-analysis of the GSTM1, GSTT1, and GSTP1 polymorphisms and prostate cancer: a HuGE review. Prostate 2009;69:662-88.
32. Hokaiwado N, Takeshita F, Naiki-Ito A, Asamoto M, Ochiya T, Shirai T. Glutathione S-transferase pi mediates proliferation of androgen-independent prostate cancer cells. Carcinogenesis 2008;29:1134-8. (Pubitemid 351958691)
33. Nelson WG, De Marzo AM, Deweese TL, Lin X, Brooks JD, Putzi MJ, et al. Preneoplastic prostate lesions: an opportunity for prostate cancer prevention. Ann N Y Acad Sci 2001;952:135-44. (Pubitemid 34060016)
34. Agalliu I, Langeberg WJ, Lampe JW, Salinas CA, Stanford JL. Glutathione S-transferase M1, T1, and P1 polymorphisms and prostate cancer risk in middle-aged men. Prostate 2006;66:146-56. (Pubitemid 43191236)
35. Hall SK, Perregaux DG, Gabel CA, Woodworth T, Durham LK, Huizinga TW, et al. Correlation of polymorphic variation in the promoter region of the interleukin-1 beta gene with secretion of interleukin-1 beta protein. Arthritis Rheum 2004;50:1976-83. (Pubitemid 38725110)
36. Kimura R, Nishioka T, Soemantri A, Ishida T. Cis-acting effect of the IL1B C-31T polymorphism on IL-1 beta mRNA expression. Genes Immun 2004;5:572-5. (Pubitemid 39529974)
37. Michaud DS, Daugherty SE, Berndt SI, Platz EA, Yeager M, Crawford ED, et al. Genetic polymorphisms of interleukin-1B (IL-1B), IL-6, IL-8, and IL-10 and risk of prostate cancer. Cancer Res 2006;66:4525-30.
38. Lee KM, Kang D, Park SK, Berndt SI, Reding D, Chatterjee N, et al. Nitric oxide synthase gene polymorphisms and prostate cancer risk. Carcinogenesis 2009;30:621-5.
39. Cronauer MV, Ince Y, Engers R, Rinnab L, Weidemann W, Suschek CV, et al. Nitric oxide-mediated inhibition of androgen receptor activity: possible implications for prostate cancer progression. Oncogene 2007;26:1875-84. (Pubitemid 46474631)
40. Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 2003;169:517-23. (Pubitemid 36132976)
41. Ahn J, Kibel AS, Park JY, Rebbeck TR, Rennert H, Stanford JL, et al. Prostate cancer predisposition loci and risk of metastatic disease and prostate cancer recurrence. Clin Cancer Res 2011;17:1075-81.
42. Cheng I, Plummer SJ, Neslund-Dudas C, Klein EA, Casey G, Rybicki BA, et al. Prostate cancer susceptibility variants confer increased risk of disease progression. Cancer Epidemiol Biomarkers Prev 2010;19:2124-32.
43. Gallagher DJ, Vijai J, Cronin AM, Bhatia J, Vickers AJ, Gaudet MM, et al. Susceptibility loci associated with prostate cancer progression and mortality. Clin Cancer Res 2010;16:2819-32.